Perspective Therapeutics, Inc.

$3.77+3.86%(+$0.14)
TickerSpark Score
50/100
Mixed
70
Valuation
20
Profitability
15
Growth
84
Health
60
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CATX research report →

52-Week Range43% of range
Low $1.96
Current $3.77
High $6.16

Companywww.perspectivetherapeutics.com

Perspective Therapeutics, Inc. , together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

CEO
Johan Spoor
IPO
2005
Employees
138
HQ
Seattle, WA, US

Price Chart

+33.22% · this period
$5.65$3.85$2.05May 20Nov 18May 20

Valuation

Market Cap
$291.23M
P/E
-3.51
P/S
506.49
P/B
1.12
EV/EBITDA
-2.17
Div Yield
0.00%

Profitability

Gross Margin
-358.09%
Op Margin
-20871.83%
Net Margin
-19327.48%
ROE
-41.84%
ROIC
-31.33%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-103,121,000 · -30.07%
EPS
$-1.40 · -13.82%
Op Income
$-113,564,000
FCF YoY
-30.98%

Performance & Tape

52W High
$6.16
52W Low
$1.96
50D MA
$4.29
200D MA
$3.62
Beta
1.76
Avg Volume
1.47M

Get TickerSpark's AI analysis on CATX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 2, 26Martinez Maria Eother50,000
Mar 2, 26Morich Frankother50,000
Mar 2, 26Williamson Robert F IIIother50,000
Mar 2, 26HENSON HEIDIother50,000
Mar 2, 26Woods Lori Aother50,000
Mar 2, 26Spoor Johan M.other735,000
Mar 2, 26Hunt Jonathan Robertother90,000
Mar 2, 26Puhlmann Markusother150,000
Nov 13, 25Hunt Jonathan Robertbuy11,000
Nov 12, 25Williamson Robert F IIIbuy9,498

Our CATX Coverage

We haven't published any research on CATX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate CATX Report →

Similar Companies